waiting and watching.. 👀

There are a handful of tickers in medical and/or cannabis pharma I've had on my watchlists or bought into..

While some caught my eye early, there are others I've just recently become aware of.

Many Oz companies can grow, produce and distribute overseas... quite a lot of international companies base growing/distribution operations in Europe, some can produce or grow here but only distribute their products overseas.. some are able to produce, grow, develop and distribute domestically... many combinations depending on what area of the industry they occupy,and the economic and political red-tape 🛑

This can be for a few  reasons. Different licensing is the big one.

Timing can be a big factor too. If a company set up at a time when or where certain laws applied, it could be a determining factor in where they based their main business operations, or even which direction to take a company in.

Then they have Cortexa.  One of the few in the world with validated psychedelic drugs ready for patient use, and since 2023 saw legislation that allows psychiatrists to prescribe here, they are in a good position on that supply chain. Of course Vitura have other brands developing  and producing cannabis products, like Inscape and Adaya. Both boasting rigorous testing and development on their flowers to create the "best products possible for the consumer"

There are some I watch that aren't specifically asx cannabis companies. Anything with great results and potential for good earnings is worth a look.  Also, anything disruptive to an established space is going to have an impact.

is a more recent discovery developing liver and pancreatic cancer therapies, I became aware of this just late last year

Positive results in trials and a few multi purpose drugs in their pipeline made it something worth looking into. At the time it was coming off historic low, also an attractive incentive 😉 FDA approvals were looking good, and can now say, has been granted

is definitely one that got away 🐠 I remember buying and selling this in the 70-90's. Now almost double that, it's one like Botanix, I should have bought back then on a set-&-forget basis! At the time I think I just sold on a good leg-up, and not knowing charts very well didnt realise it was the start of much longer growth.. oh well, I keep it on list as the reminder that everything should be Win or Learn!

I guess I like Biotechnology with its landscapes of clinical trials and results, production for public, and marketing side. It's great to see the new ways they are actually developing therapies for those with cancer, dementia, diabeties, obesity, chronic pain, dermatological issues, fertility issues, nerve and skin damage...the list is endless. While I look in many areas I'd mainly focused on asx cannabis as it's an area ripe for opportunity in Australia- we currently only have some medical access here, bar one tiny state that decriminalised it. The medical discoveries with Marijuana are abundant, we have some in Biotechnology side finding new uses in topical creams or eye emulsions for eg, some more on the growth side, taking advantage of laws against smoking being lifted or changed overseas-growing slowly but ripe for when they lift laws here..! Many of our profitable non-medical brands are doing well overseas with carefully cultivated flower  products for consumers but hopefully soon they can do more business domestically as well.